Search

Displaying results 4871 - 4880 of 10000 in total
  1. Drug

    Teduglutide

    go.drugbank.com/drugs/DB08900
    ApprovedInvestigational

    Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. … The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.

    Categories: Compounds used in a research, industrial, or household setting, Glucagon-like Peptide-2 (GLP-2) AgonistsSynonyms: Gly(2)-GLP-2, (Gly2)GLP-2
  2. Drug

    Testosterone cypionate

    go.drugbank.com/drugs/DB13943
    ApprovedInvestigational

    It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979. … Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: DEPO-TESTOSTERONE STERILE SOLUTION 100 mg/ml, DEPO-TESTOSTERONE STERILE SOLUTION 200 mg/ml
  3. Target

    Inosine-5'-monophosphate dehydrogenase 1

    go.drugbank.com/bio_entities/BE0000761
    TargetEnzymeHumans

    Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays

    Polypeptides: Inosine-5'-monophosphate dehydrogenase 1Synonyms: IMPD 1, IMPDH 1
  4. Target

    DNA (cytosine-5)-methyltransferase 1

    go.drugbank.com/bio_entities/BE0000892
    TargetHumans

    DNA methyltransferase that methylates CpG residues (PubMed:17200670, PubMed:18754681, PubMed:21745816, PubMed:26070743). Preferentially methylates hemimethylated DNA (PubMed:21745816, PubMed:26070743). Associates with DNA replication sit...

    Polypeptides: DNA (cytosine-5)-methyltransferase 1Function: DNA (cytosine-5-)-methyltransferase activity
  5. Target

    Sphingosine 1-phosphate receptor 5

    go.drugbank.com/bio_entities/BE0002432
    TargetHumans

    Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues.

    Polypeptides: Sphingosine 1-phosphate receptor 5Synonyms: S1P receptor 5, Sphingosine 1-phosphate receptor Edg-8
  6. Drug

    Interferon alfa-n1

    go.drugbank.com/drugs/DB00011
    ApprovedWithdrawn

    Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.

    Categories: Interferon Type I, Cytochrome P-450 CYP1A2 InhibitorsSynonyms: Interferon alfa-n1, Interferon alpha-n1 (INS)
  7. Drug

    Insulin human

    go.drugbank.com/drugs/DB00030
    ApprovedInvestigational

    Afrezza does not currently have Health Canada or European Medicines Agency approval for marketing in Canada or the EU. … Due to its quick onset of action, human insulin is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas

    Mixtures: INSUMAN COMB 25 100I E/ML, INSUMAN COMB 25 100I E/MLCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  8. Drug

    Racementhol

    go.drugbank.com/drugs/DB14123
    ApprovedInvestigational

    Mixtures: NuDroxiPAK E-400, E Mei Shan MedicatedSynonyms: (1R,2S,5R)-Menthol, p-Menthan-3-ol
  9. Drug

    Vurolenatide

    go.drugbank.com/drugs/DB18440
    Investigational

    Vurolenatide is a recombinant fusion protein comprising exenatide and XTEN.

    Synonyms: GLP-1-XTEN, L-HISTIDYLGLYCYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-.ALPHA.-ASPARTYL-L-LEUCYL-L-SERYL-L-LYSYL-L-GLUTAMINYL-L-METHIONYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.
  10. Drug

    Enfortumab vedotin

    go.drugbank.com/drugs/DB13007
    ApprovedInvestigational

    [L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: PADCEV 20 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ , 1 ADET, PADCEV 30 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ , 1 ADET